Loading stock data…
$52.87-0.46 (-0.86%)
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Eton Pharmaceuticals, Inc. in the Healthcare sector is trading at $54.57 with a market capitalization of $1.7B. Wall Street consensus targets $71.00 (4 analysts), implying a +30.1% move over the next 12 months. The stock is currently 18% below its 52-week high of $66.37, remaining 62.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $37.59M↑ | $24.27M↑ | $21.28M↓ | $22.46M↑ | $18.93M |
| Gross Profit | $25.41M↑ | $14.73M↑ | $13.10M↑ | $7.86M↓ | $11.92M |
| Operating Income | $12.79M↑ | $2.41M↓ | $2.46M↑ | -$1.36M↑ | -$1.48M |
| Net Income | $11.58M↑ | $1.55M↑ | $1.48M↑ | -$1.93M↑ | -$2.58M |
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle...